Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States.
Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care.
Written by:
Degraff DJ, Robinson VL, Shah JB, Brandt WD, Sonpavde G, Kang Y, Liebert M, Wu XR, Taylor JA 3rd. Are you the author?
Vanderbilt University Medical Center, Nashville, Tennessee; University of Chicago, Chicago, Illinois; University of Texas MD Anderson Cancer Center, Houston, Texas; Johns Hopkins University, Baltimore, Maryland; University of Alabama, Birmingham, Alabama; Princeton University, Princeton, New Jersey; Society for Clinical and Translational Science, Washington, District of Columbia; New York University, New York, New York; and University of Connecticut Health Center, Farmington, Connecticut.
Reference: Mol Cancer Ther. 2013 Jan 31. Epub ahead of print.
doi: 10.1158/1535-7163.MCT-12-0508
PubMed Abstract
PMID: 23269072
UroToday.com Bladder Cancer Section
